Taxoprexin
Phase 2- Indications
- Cancer
Company intelligence / Profile preview
Protarga was a clinical-stage pharmaceutical company focused on developing targeted therapies for cancer and other serious diseases using its proprietary fatty acid vector technology. Its lead program was a paclitaxel-fatty acid conjugate that advanced to late-stage clinical trials. The company collaborated with the National Cancer Institute and had several programs in preclinical or early development at the time of its acquisition in 2003.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Protarga, Inc..